Literature DB >> 20459324

Treatment of bacterial prostatitis.

Benjamin A Lipsky1, Ivor Byren, Christopher T Hoey.   

Abstract

Prostatitis is characterized by voiding symptoms and genitourinary pain and is sometimes associated with sexual dysfunction. Up to 25% of men receive a diagnosis of prostatitis in their lifetime, but <10% have a proven bacterial infection. The causes and treatment of nonbacterial prostatitis are largely unknown, but bacterial prostatitis is caused by infection with uropathogens, especially gram-negative bacilli, although infection is sometimes due to gram-positive and atypical microorganisms. Acute bacterial prostatitis is easily diagnosed (by abrupt urogential and often systemic symptoms, along with bacteriuria) and treated (by systemic antibiotic therapy). Chronic bacterial prostatitis is characterized by prolonged or recurrent symptoms and relapsing bacteriuria; diagnosis traditionally requires comparing urinary specimens obtained before with specimens obtained after prostatic massage. Treating chronic bacterial prostatitis requires prolonged therapy with an antibiotic that penetrates the prostate (ie, one with high lipid solubility, a low degree of ionization, high dissociation constant, low protein binding, and small molecular size). We review recent pharmacological and clinical data on treating bacterial prostatitis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20459324     DOI: 10.1086/652861

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  42 in total

1.  Tigecycline treatment of urinary tract infection and prostatitis: case report and literature review.

Authors:  Duane Bates; Mike Parkins; Robin Hellweg; Kimberly Gibson; Jennifer M Bugar
Journal:  Can J Hosp Pharm       Date:  2012-05

2.  Enterococcus faecalis-related prostatitis successfully treated with moxifloxacin.

Authors:  Benoît Pilmis; Hervé Lécuyer; Olivier Lortholary; Caroline Charlier
Journal:  Antimicrob Agents Chemother       Date:  2015-09-08       Impact factor: 5.191

3.  Racial differences in the relationship between clinical prostatitis, presence of inflammation in benign prostate and subsequent risk of prostate cancer.

Authors:  B A Rybicki; O N Kryvenko; Y Wang; M Jankowski; S Trudeau; D A Chitale; N S Gupta; A Rundle; D Tang
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-12-01       Impact factor: 5.554

Review 4.  Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents.

Authors:  Daniel Gonzalez; Stephan Schmidt; Hartmut Derendorf
Journal:  Clin Microbiol Rev       Date:  2013-04       Impact factor: 26.132

5.  Activation of sphingosine kinase by lipopolysaccharide promotes prostate cancer cell invasion and metastasis via SphK1/S1PR4/matriptase.

Authors:  Cheng-Fan Lee; Andrew Dang; Elizabeth Hernandez; Rey-Chen Pong; Benjamin Chen; Rajni Sonavane; Ganesh Raj; Payal Kapur; Hsin-Ying Lin; Shang-Ru Wu; Chun-Jung Ko; U-Ging Lo; Hsin-Yu Lee; Jer-Tsong Hsieh; Ming-Shyue Lee
Journal:  Oncogene       Date:  2019-05-31       Impact factor: 9.867

6.  Clinical Importance of Histopathological Inflammation in Patients with Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Prospective Study of 222 Patients.

Authors:  Thibault Meert; Evert Baten; Koenraad van Renterghem
Journal:  Curr Urol       Date:  2017-07-30

7.  Salmonella prostatitis in a man with spinal cord injury.

Authors:  Jörg Krebs; Konrad Göcking; Jürgen Pannek
Journal:  J Spinal Cord Med       Date:  2013-11-26       Impact factor: 1.985

8.  A host defense mechanism involving CFTR-mediated bicarbonate secretion in bacterial prostatitis.

Authors:  Chen Xie; Xiaoxiao Tang; Wenming Xu; Ruiying Diao; Zhiming Cai; Hsiao Chang Chan
Journal:  PLoS One       Date:  2010-12-07       Impact factor: 3.240

9.  Tamsulosin alters levofloxacin pharmacokinetics in prostates derived from rats with acute bacterial prostatitis.

Authors:  Guo-Dong Qin; Ming-Zhao Xiao; Yuan-Da Zhou; Jing Yang; Hai-Xia He; Yue He; Yang Zeng
Journal:  Asian J Androl       Date:  2013-01-28       Impact factor: 3.285

10.  Susceptibility to alternative oral antimicrobial agents in relation to sequence type ST131 status and Coresistance phenotype among recent Escherichia coli isolates from U.S. veterans.

Authors:  James R Johnson; Sarah M Drawz; Stephen Porter; Michael A Kuskowski
Journal:  Antimicrob Agents Chemother       Date:  2013-07-22       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.